SOD1 and amyotrophic lateral sclerosis: VALOR was a phase III, randomized, double-blind, placebo-controlled study that has evaluated the efficacy, safety, tolerability, and pharmacodynamic effects of tofersen on ALS with a confirmed SOD1 mutation (NCT02623699).